Oral Immunotherapy with Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection

Estelle F. Chiari, William Weiss, Michael R. Simon, Stephan T. Kiessig, Mark Pulse, Stephen C. Brown, Hanne R. Gerding, Maurice Mandago, Karina Gisch, Christoph Von Eichel-Streiber

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P =. 018 and. 039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.

Original languageEnglish
Pages (from-to)1394-1397
Number of pages4
JournalJournal of Infectious Diseases
Volume224
Issue number8
DOIs
StatePublished - 15 Oct 2021

Keywords

  • Clostridioides difficile infection
  • immunotherapy
  • secretory IgA

Fingerprint

Dive into the research topics of 'Oral Immunotherapy with Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection'. Together they form a unique fingerprint.

Cite this